Molecular Phenotype Classification via Network Topology

The patent transforms the analysis from traditional statistical comparison in gene expression space to topological analysis in network space. By mapping genes to nodes in a biological interaction network and analyzing the topological structure of differentially expressed genes, the method captures functional relationships and pathways that simple statistical methods miss, thereby improving biomarker identification accuracy through dimensional transformation from 1D expression values to nD network topology.

The patent introduces a biological interaction network as an intermediary structure between raw gene expression data and biomarker identification. This network serves as a mediator that integrates gene expression data with known biological relationships, allowing the analysis to leverage both experimental data and prior biological knowledge, thus improving identification accuracy without requiring direct complex statistical comparisons of all genes.

The patent merges individual gene expression data into a cohesive network topology structure. By combining information from multiple differentially expressed genes and their interconnections within the biological network, the method creates a unified topological signature that represents the collective behavior of gene pathways. This merging approach filters out individual gene noise and redundancy while maintaining analytical efficiency through topological summarization.

The patent changes the analytical parameter from individual gene expression levels to topological properties of gene networks (such as connectivity patterns, cluster structures, and network motifs). This parameter transformation shifts the focus from noisy individual measurements to robust structural characteristics that are less sensitive to random variation, thereby improving reliability while maintaining computational tractability through topological metrics.

The patent segments the homogeneous disease patient population into distinct molecular subtypes based on topological signatures of their gene expression networks. By dividing patients into subgroups with characteristic network topologies (e.g., different cluster patterns, connectivity structures, or pathway activation profiles), the method enables targeted treatment strategies for each subtype, improving overall treatment success rates while maintaining operational simplicity through automated classification.

The patent applies local quality by tailoring treatment approaches to specific molecular subtypes identified through topological analysis. Each patient subgroup receives treatment optimized for their particular network topology characteristics, such as specific pathway dysregulations or gene cluster patterns. This localized treatment strategy improves reliability by matching therapy to the specific molecular phenotype rather than applying uniform treatment to all patients.

The patent moves from oversimplified univariate biomarker analysis to multivariate topological analysis of gene networks. By examining the dimensional structure of gene co-expression patterns and network connectivity rather than single gene expressions, the method captures complex molecular signatures that accurately reflect disease subtypes. This dimensional enhancement improves patient identification accuracy while maintaining diagnostic efficiency through automated topological feature extraction.

The patent creates composite biomarker signatures by combining multiple gene expression measurements into a unified topological profile. Rather than relying on single biomarkers, the method synthesizes information from numerous genes organized in network structures, creating a composite signature that robustly characterizes molecular phenotypes. This composite approach improves accuracy by distributing the diagnostic signal across multiple correlated measurements while preserving operational simplicity through topological summarization.